Albert Kaplan
Family · Huntington, WVNPI 1184664518
Payments from drug & device makers
Across 95 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$332
- Sumitomo Pharma America, Inc.$211
- AbbVie$161
- Dendreon Pharmaceuticals LLC$144
- Bayer$140
- Endo USA, Inc.$134
- plus $957 from 19 others
What the payments were for
- Food & beverage$1,98095%
- Education$995%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 15 | $332 |
| Sumitomo Pharma America, Inc. | 10 | $211 |
| AbbVie | 9 | $161 |
| Dendreon Pharmaceuticals LLC | 5 | $144 |
| Bayer | 5 | $140 |
| Endo USA, Inc. | 5 | $134 |
| Tolmar, Inc. | 4 | $102 |
| Johnson & Johnson | 4 | $97 |
| Axonics, Inc. | 5 | $88 |
| Novartis | 5 | $87 |
| Merck | 4 | $76 |
| Boston Scientific | 3 | $70 |
| Coloplast | 3 | $66 |
| Procept Biorobotics Corporation | 3 | $59 |
| Endo Pharmaceuticals Inc. | 2 | $48 |
| Myriad Genetic Laboratories, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $37 |
| Medtronic | 2 | $33 |
| 180 Medical, Inc. | 1 | $29 |
| Rochester Medical Corporation | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Accord Healthcare, Inc. | 1 | $19 |
| Pfizer | 1 | $13 |
How this compares
$2,079 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 50 | $45,153 |
| GemtesaVibegron | 17 | $12,184 |
| Testosterone | 78 | $9,310 |
| Methenamine Hippurate | 50 | $3,437 |
| Testosterone Cypionate | 70 | $2,172 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 154 | $2,025 |
| Tamsulosin Hcl | 149 | $1,820 |
| Estradiol | 18 | $1,309 |
| Dutasteride | 52 | $1,068 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $706 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 22 | $497 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 53 | $455 |
| Finasteride | 50 | $446 |
| Cephalexin | 28 | $436 |
| Ciprofloxacin Hcl | 65 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $332 | $45,15350 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $211 | $12,18417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.
Other family in Huntington
- Jennifer FieldsHuntington$32K
- Misty BareboHuntington$25K
- Anne GharibHuntington$23K
- Mary VaughnHuntington$10K
- Maegen BrennanHuntington$10K
- Betty WaddellHuntington$10K
- Lana TrentHuntington$9K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.